Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) antibody
Quick Overview for Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) antibody (ABIN7824740)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Expression System
- HEK293
-
Purpose
- Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (2B2) (MALS verified)
-
Characteristics
- Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (2B2) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
-
Purification
- Protein A purified / Protein G purified
-
Purity
- 95% as determined by SDS-PAGE.
-
Sterility
- 0.22 μm filtered
-
Isotype
- IgG1, kappa
-
-
-
-
Application Notes
- ELISA: 0.03-31 ng/ml
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
-
Handling Advice
- Please avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C,-80 °C
-
Storage Comment
- For long term storage, the product should be stored at lyophilized state at -20°C or lower. This product is stable after storage at: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
-
-
- Nipah Virus Post-Fusion Glycoprotein (NIV pF)
-
Alternative Name
- Nipah Virus Post-Fusion Glycoprotein
-
Background
- Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the co
Target
-